Didactic Series. Non-Infectious Complications of HIV. Ankita Kadakia, MD UC San Diego, Owen Clinic November 8, 2018
|
|
- Camilla Fox
- 5 years ago
- Views:
Transcription
1 Didactic Series Non-Infectious Complications of HIV Ankita Kadakia, MD UC San Diego, Owen Clinic November 8,
2 Disclosures The following presenter have disclosed the following relationship with a commercial interest. Ankita Kadakia,MD Type of relationship: Spouse, Proteus Digital Resolution: This presentation has been reviewed by the PAETC Clinical Director, who reports the above disclosures have had no affect on the content of this presentation. All other presenters of this continuing medical education activity have indicated that neither they nor their spouse/legally recognized domestic partner has any financial relationships with commercial interests related to the content of this activity. 2
3 Learning Objectives 1) To understand how HIV/AIDS affects multiple organ systems and the related noninfectious complications 2) To understand how the use of ART affects multiple organ systems and related noninfectious complications 3) To understand the role of HIV/AIDS in the aging process 3
4 Poll Question Which of the following are risk factors for osteoporosis in PLWHIV? A. Smoking B. HIV C. Hypogonadism D. Low BMI E. Only A and D F. All of the above 4
5 2489 patient with HIV followed for 3 years for hip fracture vs noninfected cohort When traditional risk factors of smoking, low BMI, age, gender, glucocorticoid use, hypogonadism, comorbid conditions were adjusted for they showed that HIV was independently was higher risk than non-hiv patients May be related to proinflammatory affects of HIV and side effects of ART 5
6 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
7 Effective Treatment Saves Lives 7
8 HIV and Aging PLWHIV are living longer and now seeing diseases of older age which was not previously seen before due to the success of cart PLWHIV who take ART are more likely to die of noninfectious complications vs infectious complications of HIV HIV can accelerate noninfectious diseases such as CV events since HIV acts as a proinflammatory state What are PLWHIV on successful ART dying from? Frailty Cardiovascular events- MI/CVA Diabetes related complications Malignancies
9 Analysis of longitudinal data from Modena HIV Metabolic Clinic (MHMC) cohort study in Modena, Italy Measuring frailty as a predictor of mortality using a frailty index score in 963 participants Frailty index scores at baseline and either died or were followed for four years
10 Frailty Index Frailty index score is calculated as the proportion of health deficits present out of all health variables considered Health variables can include CKD, osteoporosis, hypercholesterolemia, proteinuria and many others CD4 nadir, years of ART, age at diagnosis, co-morbidities, viral hepatitis Greater the frailty index score the higher the mortality rate
11 Female sex, higher current and nadir CD4 cell counts, and fewer smoking pack years had lower frailty index scores indicating lower mortality rates Frailty index scores can change over time with modifiable risks such as smoking How well someone with HIV ages depends on how frail they are
12 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
13
14
15
16 Increased prevalence of smoking 2-3 times higher than general population in PLWHIV Increase due to low socioeconomic and educational levels, psychiatric comorbidity, concurrent illicit drug and alcohol use, and mental stress which are all higher in PLWHIV Current smokers had a significantly higher risk for all-cause mortality than former smokers and never smokers when controlling for age, race, sex, CD4 count, viral load COPD is more common and emphysema is accelerated in HIV-infected patients Other diseases such as periodontal disease, osteoporosis, HPV oral cancer and anal cancer increased with HIV + smoking than HIV alone or general population HIV/AIDS CID 2013:57 (15 July) 275
17
18 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
19 Bone Loss and HIV Bone loss may occur not only due to HIV/AIDS but also as a consequence of HAART Estimated that 15% of PLWHIV develop osteoporosis and 52% osteopenia Protease inhibitors and TDF are highest amongst ART regimens for causing osteoporosis Bone loss is multifactorial- unclear if direct effect of HIV or as a consequence of traditional osteoporosis risk factors associated with patient lifestyle (smoking and alcohol consumption) Other AIDS-associated diseases like muscle wasting, kidney disease, and hypogonadism, low vitamin D levels increase bone loss Curr Opin Endocrinol Diabetes Obes Dec; 17(6):
20 Meta-analysis of 20 studies conducted Jan Nov 2005 Compared HIV-positive vs HIV-negative; ART-treated vs ART-naive;protease inhibitor (PI)- treated vs PI-untreated Of the 884 HIV-infected patients, 67% had reduced BMD, of whom 15% had osteoporosis compared with HIV-uninfected controls (n.654) using 11 studies with available data. Compared with ART-naive patients (n.202, 10 studies),art-treated individuals (n.824) had a 2.5-fold increased odds of prevalent reduced BMD. The risk of prevalent osteoporosis (seven studies) was similarly elevated in ARTtreated individuals. Compared with non-pi-treated HIV patients (n.410, 14 studies),pi-treated patients (n.791) had increased odds of reduced BMD and osteoporosis (12 studies) Prevalence of osteoporosis in HIV-infected individuals is more than three times greater compared with HIV-uninfected controls. ART-exposed and PI exposed individuals had a higher prevalence of reduced BMD and osteoporosis compared with their respective controls CIDS 2006, 20:
21 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
22 Poll Question Distal sensory polyneuropathy is the most common form of HIV associated neuropathy. Which of the following are risk factors for the development of neuropathy in PLWHIV? A. Low CD4 count B. Longer duration of untreated HIV C. High viral load D. Older age E. A, B, and C F. All of the above 22
23 HIV associated Neuropathy MC pain syndrome ~ 33% of PLWHIV affected Can occur as a complication of HIV/AIDS or related to ART NRTIs most common ART, incidence of neuropathy is related to the degree of mitrochondrial toxicity with certain nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine and stavudine inhibit mitochondrial DNA synthesis more tightly than zidovudine, lamivudine Hypothesized that the HIV-1 envelope protein (gp120) may cause neuronal injury indirectly through Schwann cells by inducing upregulation of TNF-alpha, which may result in apoptotic death of sensory neurons
24
25
26 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
27 Grand Rounds Michael Rubin, MD Department of Ophthalmology and Visual Science The University of Chicago HIV Retinopathy Most common retinal pathology in HIV, occurs in as many as 50-70% of PLWHIV Often manifests as cotton-wool spots Etiology is increased plasma viscosity, immune-complex deposition, and a direct cytopathic effect of HIV on the retinal vascular endothelium The arteriolar occlusion in HIV microvasculopathy leads to interruption of the axoplasmic flow, which manifests as cotton-wool spots No treatment except ART
28
29 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
30 Noninfectious Pulmonary HIV Malignancy Inflammatory Pulmonary Vasculature AIDS Defining Non-AIDs Defining LIP NSIP Pulmonary HTN
31 Lung Malignancy AIDS-Defining HHV-8, EBV Kaposi s sarcoma Primary effusion lymphoma Non-Hodgkin s Lymphoma Am J Med Sci Dec;348(6):502-11
32 Lung Malignancy Non-AIDS Defining Higher incidence than general population even with ART use Unclear etiology but increased tobacco use and level of immunosuppression related Occur at younger age, ~48 compared with gen population ~60, more aggressive advanced forms Adenocarcinoma is MC form Screening is similar to general population 32
33 Inflammatory Lymphocyte Interstitial Pneumonia- influx of lymphocytes into alveolar space, includes NSIP HIV-related proteins in germinal centers, pulmonary interstitium and BAL as likely a direct cause of HIV May be related to immune reconstitution inflammatory syndrome
34 Pulmonary Vasculature Pulmonary HTN Incidence estimated at 0.5% which represents relative risk of 1000 fold compared with general population Worse prognosis for PLWHIV + PH compared to PLWHIV alone Inflammation, genetics, intravenous drug use, coinfections and viral proteins may contribute Gp120 has been shown to target pulmonary endothelial cells and increase secretion of endothelin-1, a potent vasoconstrictor
35 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
36 Noninfectious Gastrointestinal HIV Complications Nausea and Vomiting 2/2 to ART Chronic diarrhea 2/2 HIV enteropathy Pancreatitis 2/2 ART stavudine, didanosine, NRTIs, dolutegravir
37 HIV Enteropathy Chronic, well-established diarrhea (> 1 month duration) with no identified infectious cause after thorough evaluation Related to direct or indirect effects of HIV on the enteric mucosa a diagnosis of exclusion made after other forms of diarrheal illness have been ruled out Diarrhea 2/2 to ART : PI > NRTI> NNRTI > INSTI Gut-associated lymphoid tissue (GALT) is the largest collection of lymphoid tissue in the human body Persistent stimulation of the immune system by HIV in the gut Baseline inflammatory state that encourages the production of proinflammatory chemokines which mediate the movement of lymphocytes into the mucosal tissues, damage to gut epithelial cells ( gp 120), depletion of gut CD4 cells but increased CD8 cell that are primed to produce cytokines which may damage the mucosal barrier Even after starting ART, diarrhea can persists due to the damage of gut mucosa by HIV Dig Dis Sci. 2015; 60(8):
38
39
40 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
41 Poll Question 60 Y AA M with CD4 20, VL 1mil, new dx, presents on initial visit with flank pain. You obtain an UA which shows 3+ proteinuria and Cr 4.0, no baseline to compare. What should you do next? A. Obtain a renal biopsy to confirm FSGS B. Start ART immediately C. Obtain a renal US D. A and C 41
42 HIV Associated Nephropathy (HIVAN) Complication of untreated advanced HIV/AIDS Most predominant in African Americans with 90% of cases Rapidly progressive renal failure Moderate to nephrotic range proteinuria Bland urinary sediment Ultrasound findings of large, highly echogenic kidneys HIVAN is a collapsing glomerulopathy of focal segmental glomerulosclerosis (FSGS)
43 HIVAN Pathogenesis of HIVAN requires local HIV infection of the kidney, with the virus infecting tubular and glomerular epithelial cells ART is effective at preventing and reversing HIVAN hence should be started immediately even without a genotype HIVAN has become less prevalent with ART use
44 Semin Nephrol Nov; 28(6):
45 Tenofovir related Fanconi Syndrome Tenofovir disoproxil fumarate affects the proximal renal tubule Glucosuria, proteinuria, elevated urine potassium Hypokalemia, hypophophatemia, metabolic acidosis TDF has higher circulating plasma levels leading to more renal and bone disease vs TAF which goes directly to tissue causing lower plasma concentrations
46 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system
47 Hypogonadism Occurs more frequently in poorly controlled or uncontrolled HIV/AIDS but prevalence is decreasing with ART Measured by morning (before 10am) total testosterone Male hypogonadism can lead to osteoporosis, erectile dysfunction/decreased libido, reduced lean body mass/muscle strength, depression, and the metabolic syndrome Used to be more frequent among men with the AIDS and was attributed to testicular dysfunction due to opportunistic infections, cancers, wasting syndrome, and cytokine disorders With ART use, now found to be related to hypothalamicpituitary axis impairment, aging,and comorbidities (alcoholism, hepatitis C, and injecting drug use) AIDS: January 28th, Volume 31 - Issue 3 - p
48 Prospective observational study of 33,389 HIV-infected patients; diabetes is a study end point 744 patients or incidence rate of 5.72 per 1,000 person year follow up The incidence of diabetes increased with cumulative exposure to cart, an association that remained significant after adjustment for potential risk factors for diabetes NRTIs and Protease Inhibitors cause insulin resistance leading to increased blood glucose levels and Type 2 diabetes Do not need to stop or change ART, lifestyle modification followed by diabetes medication Consider avoiding PI if a patient already has diabetes prior to HIV diagnosis
49 Thank you! 49
NORTHWEST AIDS EDUCATION AND TRAINING CENTER. HIV and the Kidney. Leah Haseley, MD. Presentation prepared by: LH NW AETC ECHO June 2012
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and the Kidney Leah Haseley, MD Presentation prepared by: LH NW AETC ECHO June 2012 Etiology of renal disease in HIV 1985- The virus 1995- The antivirals
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More informationC E L I A J. M A X W E L L, M. D
H I V / A I D S I N O L D E R I N D I V I D U A L S T H E G R A Y I N G O F T H E D I S E A S E E X T E N U A T I N G V S M I T I G A T I N G F A C T O R S C E L I A J. M A X W E L L, M. D., F A C P A
More informationHIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER
HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER Gaston Zilleruelo M.D. Professor of Pediatrics Director of Pediatric Nephrology University of Miami/Holtz Children s Hospital Worldwide 33.2 million
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationHIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1
HIV and Common Comorbidities August 17, 2017 Michael MacVeigh, MD & Kristen Meyers, BS, CADC1 Learning Objectives 1) Confidently discuss basics of ARVs and common side effects of these medications 2) Understand
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationDr Michael Rayment Chelsea and Westminster Hospital, London
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Michael Rayment Chelsea and Westminster Hospital, London 6-8 April 2011, Bournemouth International Centre A decade of renal biopsies in
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationAging and Cancer in HIV
Aging and Cancer in HIV Ronald Mitsuyasu, MD Professor of Medicine Director, UCLA Center for Clinical AIDS Research and Education Group Chairman, AIDS Malignancy Consortium (AMC) Age distribution of HIV-infected
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationComorbidities: a moving area. Paul De Munter ARC Leuven BREACH
Comorbidities: a moving area Paul De Munter ARC Leuven BREACH 27-11-2015 Contents Introduction Comorbidities Cardiovascular disease and lipids Diabetes mellitus Hepatitis C Frailty Conclusion Introduction
More informationHIV long term complications
HIV- 2015 long term complications 4th Asian Conference on Hepatitis & AIDS 22-23 May 2015, Xi'an, China Kees Brinkman Amsterdam The Netherlands NL 2012: known 17.000 (0,1%) treatment 85% (all) China 2011:
More informationCLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:
CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer
More informationHans Strijdom SA Heart Meeting November 2017
Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationUpdate on HIV-Related Kidney Diseases. Agenda
Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationDidactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16
Didactic Series Bone Health in the context of HIV Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 This project is supported by the Health Resources and Services Administration
More informationIncreased and accelerated age-related complications in HIV-infected patients
Increased and accelerated age-related complications in HIV-infected patients Giovanni Guaraldi Università di Modena THE CHANGING SPECTRUM OF HIV CARE Pre- HAART 1996 Early- HAART 2005 Late- HAART Opportunistic
More informationIntroduction to HIV and Aging
Introduction to HIV and Aging Sheree Starrett MD Medical Director - Rivington House June 27, 2008 Rivington House Objectives Know the demographics of aging and HIV Identify the similarities between aging
More informationTDF Renal Dysfunction
TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape
More informationHIV and your Bones Osteopenia and Osteoporosis
Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia
More informationPrimary Care for Persons Living with HIV
Primary Care for Persons Living with HIV Brian Montague, DO MS MPH Assistant Professor of Medicine Division of Infectious Diseases Warren Alpert School of Medicine Brown University Outline What constitutes
More informationDifferences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006
13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir
More informationHIV IN OKLAHOMA MAKING A DIFFERENCE
HIV IN OKLAHOMA MAKING A DIFFERENCE Madhuri Lad, DO, FACOI, AAHIVS Assistant Program and Medical Director OSU Internal Medicine Specialty Services HIV Program Clinical Assistant Professor Rashes Demographics
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationPIs are the real world answer for the chronic patient s management. Giovanni Guaraldi
PIs are the real world answer for the chronic patient s management Giovanni Guaraldi HIV MEDICATION TOXICITY Ageing with HIV: The clinical consequences AGEING Heart disease Kidney disease Liver disease
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationHIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School
HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually
More informationRenal safety of tenofovir containing antiretroviral regimen in a Singapore cohort
Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationMichael Healy August 8, 2012 Irving CRC Research Proposal. 1. Study Purpose and Rationale
Michael Healy August 8, 2012 Irving CRC Research Proposal Prevalence of diarrhea and gastrointestinal infection in severely malnourished Human Immunodeficiency Virus (HIV) infected children in Durban,
More informationOutline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose
Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationDiabetes, Obesity and Heavy Proteinuria
Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been
More informationNephrology Grand Rounds. Mansi Mehta November 24, 2015
Nephrology Grand Rounds Mansi Mehta November 24, 2015 Case 51yo F with PMH significant for Hypertension referred to renal clinic for evaluation of elevated Cr. no known history of CKD; baseline creatinine
More informationMohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi
Role of Vitamin D receptor (VDR) in HIV induced tubular injury Mohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi 07/10/2015 INTRODUCTION Vitamin D is technically not a Vitamin;
More informationHIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London
HIV/HCV co-infected patients should be prioritised for HCV treatment Sanjay Bhagani Royal Free Hospital/UCL London Also requires other resources What should a prioritisation process Life-saving at this
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationSituación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona
Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona Mortality per 1 patient-years HIV infection has changed from a fatal disease into a chronic condition This means long-term
More informationKidney Disease in HIV. Kidney Disease in HIV: An Update for Ryan White Providers
Kidney Disease in HIV: An Update for Ryan White Providers Christina M. Wyatt, MD Assistant Professor Mount Sinai School of Medicine New York, New York FORMATTED: 11/16/2015 Learning Objectives After attending
More informationFuture challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study
Future challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study Guaraldi G 1, De Francesco D 2, Malagoli A 1, Theou O 3, Zona S 1, Carli F 1, Dolci G 1,
More informationMedical Overview March 7, Nina Lambert, NP Inova Juniper Program
Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationPART VI! IMPLICATIONS FOR THERAPIES
PART VI! IMPLICATIONS FOR THERAPIES Background Current HIV and aging treatment advice: Start ART early and manage traditional risk factors for non-aids-related diseases aggressively Treatments to reverse
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More informationTOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY
SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationTra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco
Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo Cristina Gervasoni ASST FBF Sacco Outline What do I know? What do we know? What have we learned lately? Outline What do we know?
More informationTDF is particularly associated with loss of BMD
Earn 3 CPD Points online HIV infection and risk of fracture Key messages Antiretroviral therapy (ART) has increased the life expectancy of HIV-infected people, which can now match that of the uninfected
More informationOptimizing Health While Aging with HIV
Slide 1 Optimizing Health While Aging with HIV Todd T. Brown, MD, PhD Division of Endocrinology and Metabolism Johns Hopkins University Unfortunately, We are Not Slide 2 Immortal But How Do We Want to
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More information50+ SHADES OF GREY, AGING WITH HIV
50+ SHADES OF GREY, AGING WITH HIV R E B E C C A G L A S S M A N, M D I N S T R U C T O R O F M E D I C I N E, H A R V A R D M E D I C A L S C H O O L MR. C 71 years old Diagnosed with HIV in 1998 at the
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationSafety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008
Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationRenal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
Original Article Vol. 29 No. 3 Renal safety of tenofovir:- Wiwattanathum P & Sungkanuparph S. 113 Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir
More informationAttendees will be able to:
A. Kay Kalousek, DO, MS, FACOFP kaysdroid@gmail.com April 21, 2017 Attendees will be able to: List strategies for prevention of HIV infection Explain the pharmacology of TDF/FTC related to PrEP Assess
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationCOPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017
COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA
More informationEmtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationMild and Severe Adverse Effects of Antiretroviral Treatment
Mild and Severe Adverse Effects of Antiretroviral Treatment Gordon Dickinson, MD Professor of Medicine and Chief, Infectious Diseases, Miller School of Medicine, University of Miami Abacavir, available
More informationVemlidy. (tenofovir alafenamide) New Product Slideshow
Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength
More informationOdefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow
Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological
More informationEU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3
VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized
More informationAlterations of Renal and Urinary Tract Function
Alterations of Renal and Urinary Tract Function Chapter 29 Urinary Tract Obstruction Urinary tract obstruction is an interference with the flow of urine at any site along the urinary tract The obstruction
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationTarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT
The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT Normal Cell Plasma cells produce antibodies that bind to antigens,
More informationThe impact of antiretroviral drugs on Cardiovascular Health
The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,
More informationPharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS MICHELLE A. RUDEK, PHARM.D., PH.D. ASSOCIATE PROFESSOR OF ONCOLOGY AND MEDICINE JOHNS HOPKINS UNIVERSITY Disclosures Spouse Employed Novavax
More informationClinical syndromes: experience from the bedside. Professor Rob Miller University College Hospital, London
Clinical syndromes: experience from the bedside Professor Rob Miller University College Hospital, London Presented at ECCMID Berlin April 30 th 2013 Pneumocystis jirovecii pneumonia http://commons.wikimedia.org/wiki/file
More informationPaul Volberding, M.D. (Chair) Igor Grant, M.D., FRCP John G. Bartlett, M.D. H. Clifford Lane, M.D. Celia Maxwell, M.D., FACP Carlos del Rio, M.D.
HIV and Disability Committee membership Paul Volberding, M.D. (Chair) San Francisco VA Medical Center John G. Bartlett, M.D. Johns Hopkins University Carlos del Rio, M.D. Emory University Patricia M. Flynn,
More informationMetabolic complications of HIV and HAART: The hyperlactataemia syndromes
Metabolic complications of HIV and HAART: The hyperlactataemia syndromes Colin Menezes Division of Infectious Diseases Department of Internal Medicine Chris Hani Baragwanath Academic Hospital University
More informationMortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord
Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationAging and HIV: Living Life with Silver Hair
Georgia Southern University Digital Commons@Georgia Southern 6th Annual Rural HIV Research and Training Conference Sep 21st, 4:30 PM - 5:15 PM Aging and HIV: Living Life with Silver Hair Barbara J. Blake
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More information